Evaxion Biotech A/S (EVAX)
Automate Your Wheel Strategy on EVAX
With Tiblio's Option Bot, you can configure your own wheel strategy including EVAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EVAX
- Rev/Share 0.1463
- Book/Share -0.0721
- PB -1.5959
- Debt/Equity -6.1144
- CurrentRatio 2.0066
- ROIC -1.5952
- MktCap 3226005.0
- FreeCF/Share -0.0875
- PFCF -1.6082
- PE -0.2494
- Debt/Assets 0.8091
- DivYield 0
- ROE -18.5514
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast.
Read More
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments).
Read More
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM.
Read More
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
Read More
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data underscoring the ability of cancer vaccine EVX-01 to drive a targeted and robust immune response. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
Read More
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript
Published: April 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Swayampakula Ramakanth - HCW Operator Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast.
Read More
Evaxion to announce business update and full year 2024 financial results on April 1, 2025
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.
Read More
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will further enhance the data package from its ongoing phase 2 trial with the company's lead asset EVX-01 by extending the trial from two to three years. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine being developed as a treatment for advanced melanoma (skin cancer).
Read More
About Evaxion Biotech A/S (EVAX)
- IPO Date 2021-02-05
- Website https://www.evaxion-biotech.com
- Industry Biotechnology
- CEO Mr. Christian Kanstrup M.Sc.
- Employees 46